Drugs / Autologous Hematopoietic Stem cells (HSCs)
Autologous Hematopoietic Stem cells (HSCs)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03334305 | Aug 2018 → Mar 2025 | high grade astrocytic tumor | University of Florida | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06254326 Background | Sep 2024 → Dec 2027 expected | oligodendroglioma | University of Florida | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Hematopoietic Stem cells (HSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03334305 ↗ |
| Modality | Cell therapy | “Autologous Hematopoietic Stem cells (HSCs)” NCT03334305 ↗ |
| Route | Intravenous | “a i.v. single infusion of autologous HSCs” NCT06254326 ↗ |